2019
conference-abstract
OpenAlex
Claire Roddie, Maeve O’Reilly, Maria A. V. Marzolini, Leigh Wood et autres
Introduction: 2nd generation CD19 CAR T cells show unprecedented efficacy in B-ALL, but several challenges remain: (1) scaling manufacture to meet patient need and (2) feasibility of generating products from lymphopenic patients post allogeneic stem cell transplant (allo-SCT). To overcome these issues …
gb
(code pays fourni par la source)
2019
conference-abstract
OpenAlex
Claire Roddie, Maeve O’Reilly, Juliana Dias, Ketki Vispute et autres
Introduction: CD19 CAR T therapy has advanced treatment of relapsed/refractory (r/r) Acute Lymphoblastic Leukemia (B-ALL). However, several challenges remain including: (1) considerable toxicity of CD19 CAR therapy; (2) the need for long-term persistence to deliver sustained response; (3) requirement for robust, cost …
gb
(code pays fourni par la source)
2019
conference-abstract
OpenAlex
Claire Roddie, Maeve O’Reilly, Juliana Dias, Ketki Vispute et autres
Abstract Introduction: CD19 CAR T therapy has advanced treatment of relapsed/refractory (r/r) Acute Lymphoblastic Leukemia (B-ALL). However, several challenges remain including: (1) considerable toxicity of CD19 CAR therapy; (2) the need for long-term persistence to deliver sustained response; (3) requirement for robust, …
gb
(code pays fourni par la source)